$AMPH

Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise

Amphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.

Original reporting
Published Aug 18, 2026, 9:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 2:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

Planned insider selling can pressure short-term sentiment, but the disclosed quantity is small and the filing does not by itself change operating fundamentals.

02

Market read

Traders may monitor AMPH for incremental selling pressure around the proposed sale date, but the magnitude is likely too small to drive a major repricing alone.

03

What to watch

Rule 144 is a notice, not a confirmation of full execution; traders should watch for subsequent Form 144 updates or larger insider transactions to gauge real supply risk.

Relevance 4/10Novelty 3/10Timing: proposed sale date listed as 08/18/2026

Background

The article summarizes an Amphastar Form 144 notice under Rule 144, which outlines conditions for restricted or insider-held shares to be resold publicly.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Amphastar filed a Rule 144 notice for Floyd Petersen to sell 47,101 shares after an option exercise, signaling planned insider supply.

Expected impact

Low likelihood of a sustained move; any impact is likely short-lived around the sale window unless follow-on filings show larger selling.

Evidence & confidence

Rule 144 notices are common and do not guarantee execution timing beyond the proposed sale date, and the stated 47,101 shares are small relative to 44.09M shares outstanding.

Market effects

Limited read-through for the specialty pharma sector; this is company-specific insider selling rather than a sector catalyst.

None.

None.

Counterpoint

The sale follows an option exercise for cash, so it may be routine liquidity management rather than a bearish view on fundamentals.

Key entities

  • Amphastar Pharmaceuticals, Inc.

    Subject of the Rule 144 notice, with an insider planned sale of 47,101 shares after option exercise.

  • Floyd Petersen

    Named selling security holder in the Rule 144 notice.

  • UBS Financial Services Inc.

    Identified as the broker/attorney-in-fact in the notice.

Related articles

$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

$AMPHMedAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

$AMPHMed

Amphastar Pharmaceuticals, Inc. (AMPH): Results of Operations and Financial Condition

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per share, for the second quarter ​ - Adjusted no

$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash